Delivering Chemotherapy Drugs Directly into Cancer Cells While Minimizing Harm

Delivering Chemotherapy Drugs Directly into Cancer Cells While Minimizing Harm Ren Homan, Ph.D., Co-Founder of Peptinovo Biopharma and Steve Tokarz, CEO of Peptinovo Biopharma   

Peptinovo Biopharma in Collaboration with Chemelectiva Announces Breakthrough Manufacturing Innovation for Targeted Chemotherapy

Peptinovo Biopharma, an Ann Arbor-based biotechnology company pioneering targeted cancer therapies through its proprietary PALM™ nanotechnology, today announced a major manufacturing and intellectual property milestone achieved in collaboration with Chemelectiva Srl, an Italian specialty pharmaceutical chemistry company. The breakthrough significantly advances Peptinovo’s proprietary prodrug platform for targeted chemotherapy delivery